Dr. Hoenle AG (DE:HNL)
XETRA:HNL
Want to see DE:HNL full AI Analyst Report?
HNL Stock Chart & Stats
€7.10
-€0.20(-2.86%)
At close: 4:00 PM EST
€7.10
-€0.20(-2.86%)
Day’s Range― - ―
52-Week Range€6.48 - €11.90
Previous CloseN/A
Volume3.05K
Average Volume (3M)6.13K
Market Cap
€57.22M
Enterprise Value€98.07M
Total Cash (Recent Filing)€6.71M
Total Debt (Recent Filing)€47.80M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.68
Shares Outstanding6,062,930
10 Day Avg. Volume3,193
30 Day Avg. Volume6,130
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)0.65
Price to Sales (P/S)0.53
P/FCF Ratio15.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€99.60M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationSustained positive operating and free cash flow provides durable internal funding for maintenance capex, R&D, and working capital. This cash buffer reduces short-term refinancing risk, enables steady aftermarket supply investments, and supports a path to profitability even if margins recover slowly.
Recurring Aftermarket Revenue & Diversified MixA business model combining system sales with consumable lamps, quartz parts and measurement instrumentation creates recurring revenue and customer stickiness. Vertical integration across systems and glass & lamps supports reliability of supply, higher aftermarket margins and steadier revenue through industrial cycles.
Revenue Recovery TrendImproving top-line and narrowing losses indicate demand stabilization and better operational leverage. When paired with positive cash flow, this trend suggests the company can scale fixed-cost absorption and pursue modest reinvestment, improving odds of durable margin recovery over coming quarters.
Bears Say
Persistent UnprofitabilityOngoing negative margins and EBIT mean the core business has yet to demonstrate sustainable profitability. Continued losses can erode equity, limit reinvestment capacity, and force difficult cost or pricing choices; sustained margin improvement is required for long-term financial health.
Negative Return On EquityA negative ROE signals capital is not generating returns for shareholders, reflecting operational underperformance. Persistently negative ROE constrains management's ability to fund growth from retained earnings and raises the likelihood of external financing or restructuring if improvement stalls.
Volatile Cash Flow & Earnings HistoryHistorical swings into negative OCF/FCF highlight exposure to cyclical industrial capex and project timing. This volatility increases funding and planning risk, making consistent investment in product development, inventory and aftermarket support harder during downturns, weighing on long-term resilience.
Dr. Hoenle AG News
HNL FAQ
What was Dr. Hoenle AG’s price range in the past 12 months?
Dr. Hoenle AG lowest stock price was €6.48 and its highest was €11.90 in the past 12 months.
What is Dr. Hoenle AG’s market cap?
Dr. Hoenle AG’s market cap is €57.22M.
When is Dr. Hoenle AG’s upcoming earnings report date?
Dr. Hoenle AG’s upcoming earnings report date is May 19, 2026 which is in 4 days.
How were Dr. Hoenle AG’s earnings last quarter?
Dr. Hoenle AG released its earnings results on Feb 24, 2026. The company reported -€0.25 earnings per share for the quarter, missing the consensus estimate of -€0.213 by -€0.037.
Is Dr. Hoenle AG overvalued?
According to Wall Street analysts Dr. Hoenle AG’s price is currently Overvalued.
Does Dr. Hoenle AG pay dividends?
Dr. Hoenle AG pays a Annually dividend of €0.2 which represents an annual dividend yield of N/A. See more information on Dr. Hoenle AG dividends here
What is Dr. Hoenle AG’s EPS estimate?
Dr. Hoenle AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dr. Hoenle AG have?
Dr. Hoenle AG has 6,062,930 shares outstanding.
What happened to Dr. Hoenle AG’s price movement after its last earnings report?
Dr. Hoenle AG reported an EPS of -€0.25 in its last earnings report, missing expectations of -€0.213. Following the earnings report the stock price went up 6.54%.
Which hedge fund is a major shareholder of Dr. Hoenle AG?
Currently, no hedge funds are holding shares in DE:HNL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dr. Hoenle AG Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.44%
12-Months-Change
Fundamentals
Return on Equity
-5.31%
Trailing 12-Months
Asset Growth
-7.47%
Trailing 12-Months
Company Description
Dr. Hoenle AG
Dr. Hönle AG supplies industrial UV technologies and systems in Germany and internationally. The company operates through three segments: Adhesives, Equipment & Systems, and Glass & Lamps. The Adhesives segment provides industrial adhesives for applications, such as consumer electronics, medical technology, optics and opto electronics, automotive, and glass processing. The Equipment & Systems segment engages in the drying of inks and coatings, curing of adhesives and plastics, disinfecting surfaces, and solar simulation. The Glass & Lamps segment offers quartz glass tubing and rods for the lamp, automotive, semiconductor, and fibre cable industries, as well as lamps for water disinfection, and the drying of coatings and adhesives. The company was founded in 1976 and is headquartered in Munich, Germany.
Technical Analysis
LPKF Laser & Electronics
―
Manz AG
―
MAX Automation
―
Singulus Technologies
―
Suss Microtec
―
Options Prices
Currently, No data available
---